Myopia is the most common eye disease in children and has
experienced a dramatic increase in prevalence over the last 30 years.
Once considered a benign refractive condition, even at low levels,
myopia is now associated with many serious ophthalmic co-
morbidities. The greater myopia severity, the higher the risk of these
ophthalmic co-morbidities later in life. Sydnexis was founded with the
goal of developing a proprietary, stable, low-dose atropine eyedrop to
treat myopia progression in children and minimize the risk of ocular
co-morbidities. At Sydnexis, we have focused on
developing a best-in-class low-dose atropine formulation to address
the juvenile-onset myopia pandemic.
Company Details
- Employees
- 21
- Founded
- -
- Address
- Del Mar, California
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://www.sydnexis.com
- HQ
- Del Mar, California
Sydnexis Questions
Sydnexis's website is https://www.sydnexis.com
Sydnexis's LinkedIn profile is https://www.linkedin.com/company/sydnexis
Sydnexis has
21 employees.
View email and phone details for 21
employees at Sydnexis.
Sydnexis's industry is
Pharmaceutical Manufacturing
Sydnexis's top competitors are
Alcon,
Tarsus Pharmaceuticals, Inc.,
Orasis Pharmaceuticals,
Harrow,
Neurotech Pharmaceuticals, Inc.,
Corium,
Ocular Therapeutix, Inc.,
Visionary Venture Fund,
Surface Ophthalmics,
Lenz Therapeutics.
Sydnexis's categories are Pharmaceutical Manufacturing
Sydnexis's founding year is 2014
